63 research outputs found
Review of an Influenza Surveillance System, Beijing, People’s Republic of China
This system enabled detection of the onset and peak of an epidemic
Aquatic therapy for boys with Duchenne muscular dystrophy (DMD): an external pilot randomised controlled trial
Background: Standard treatment of Duchenne muscular dystrophy (DMD) includes regular physiotherapy. There
are no data to show whether adding aquatic therapy (AT) to land-based exercises helps maintain motor function.
We assessed the feasibility of recruiting and collecting data from boys with DMD in a parallel-group pilot randomised
trial (primary objective), also assessing how intervention and trial procedures work.
Methods: Ambulant boys with DMD aged 7–16 years established on steroids, with North Star Ambulatory
Assessment (NSAA) score ≥8, who were able to complete a 10-m walk test without aids or assistance, were
randomly allocated (1:1) to 6 months of either optimised land-based exercises 4 to 6 days/week, defined by
local community physiotherapists, or the same 4 days/week plus AT 2 days/week. Those unable to commit to a
programme, with >20% variation between NSAA scores 4 weeks apart, or contraindications to AT were excluded.
The main outcome measures included feasibility of recruiting 40 participants in 6 months from six UK centres,
clinical outcomes including NSAA, independent assessment of treatment optimisation, participant/therapist views
on acceptability of intervention and research protocols, value of information (VoI) analysis and cost-impact analysis.
Results: Over 6 months, 348 boys were screened: most lived too far from centres or were enrolled in other trials;
12 (30% of the targets) were randomised to AT (n = 8) or control (n = 4). The mean change in NSAA at 6 months
was −5.5 (SD 7.8) in the control arm and −2.8 (SD 4.1) in the AT arm. Harms included fatigue in two boys, pain in
one. Physiotherapists and parents valued AT but believed it should be delivered in community settings. Randomisation
was unattractive to families, who had already decided that AT was useful and who often preferred to enrol in drug
studies. The AT prescription was considered to be optimised for three boys, with other boys given programmes
that were too extensive and insufficiently focused. Recruitment was insufficient for VoI analysis.
Conclusions: Neither a UK-based RCT of AT nor a twice weekly AT therapy delivered at tertiary centres is feasible.
Our study will help in the optimisation of AT service provision and the design of future research.
Trial registration: ISRCTN4100295
Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance.
Pharmacokinetic/pharmacodynamic (PKPD) modeling is important in the design and conduct of clinical pharmacology research in children. During drug development, PKPD modeling and simulation should underpin rational trial design and facilitate extrapolation to investigate efficacy and safety. The application of PKPD modeling to optimize dosing recommendations and therapeutic drug monitoring is also increasing, and PKPD model-based dose individualization will become a core feature of personalized medicine. Following extensive progress on pediatric PK modeling, a greater emphasis now needs to be placed on PD modeling to understand age-related changes in drug effects. This paper discusses the principles of PKPD modeling in the context of pediatric drug development, summarizing how important PK parameters, such as clearance (CL), are scaled with size and age, and highlights a standardized method for CL scaling in children. One standard scaling method would facilitate comparison of PK parameters across multiple studies, thus increasing the utility of existing PK models and facilitating optimal design of new studies
Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry
OBJECTIVES: The Digital Ulcers Outcome (DUO) Registry was designed to describe the clinical and antibody characteristics, disease course and outcomes of patients with digital ulcers associated with systemic sclerosis (SSc).
METHODS: The DUO Registry is a European, prospective, multicentre, observational, registry of SSc patients with ongoing digital ulcer disease, irrespective of treatment regimen. Data collected included demographics, SSc duration, SSc subset, internal organ manifestations, autoantibodies, previous and ongoing interventions and complications related to digital ulcers.
RESULTS: Up to 19 November 2010 a total of 2439 patients had enrolled into the registry. Most were classified as either limited cutaneous SSc (lcSSc; 52.2%) or diffuse cutaneous SSc (dcSSc; 36.9%). Digital ulcers developed earlier in patients with dcSSc compared with lcSSc. Almost all patients (95.7%) tested positive for antinuclear antibodies, 45.2% for anti-scleroderma-70 and 43.6% for anticentromere antibodies (ACA). The first digital ulcer in the anti-scleroderma-70-positive patient cohort occurred approximately 5 years earlier than the ACA-positive patient group.
CONCLUSIONS: This study provides data from a large cohort of SSc patients with a history of digital ulcers. The early occurrence and high frequency of digital ulcer complications are especially seen in patients with dcSSc and/or anti-scleroderma-70 antibodies
Chicken egg yolk antibodies (IgY) as non-antibiotic production enhancers for use in swine production: a review
A Bayesian decision‐theoretic approach to incorporate preclinical information into phase I oncology trials
A robust Bayesian meta-analytic approach to incorporate animal data into phase I oncology trials
Bridging across patient subgroups in phase I oncology trials that incorporate animal data
HIV‐protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO‐hybridized derivatives?
A review of current practice in the design and assessment of internal pilots in UK NIHR clinical trials
- …